Literature DB >> 8198941

The effect of liver disease and food on plasma MEGX concentrations.

R Pritchard-Davies1, A S Gross, G M Shenfield.   

Abstract

Plasma monoethylglycinexylidide (MEGX) concentrations were measured in 15 healthy controls (age 23-46 years) and 12 patients with biopsy proven cirrhosis (age 34-70 years) 30 min after 1 mg kg-1 intravenous lignocaine. Mean (+/- s.d.) MEGX concentrations were 57 +/- 33 ng ml-1 in the controls compared with 21 +/- 18 ng ml-1 in the cirrhotics (P < 0.05), but there was overlap in the range of concentrations. MEGX concentrations were inversely correlated with age, but not disease severity, in the cirrhotic patients (r = 0.62, P = 0.04) but not in the control subjects. In a second study 20 healthy subjects were given 1 mg kg-1 intravenous lignocaine on two occasions; either fed or fasted, and samples taken at 15, 30 and 60 min after dosage. MEGX concentrations were not significantly different at any time within either day or between fed and fasted study days. There was no correlation with age. The plasma lignocaine concentration at 15 min was significantly higher fed than fasted (2.88 +/- 2.44 and 1.82 +/- 0.96 micrograms ml-1, P = 0.01). Measurement of plasma MEGX after i.v. lignocaine is a useful test of liver function and may be performed in fed or fasted subjects. It is reproducible within an individual but is not specific for cirrhosis and appears age-related in liver disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8198941      PMCID: PMC1364763          DOI: 10.1111/j.1365-2125.1994.tb04279.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis.

Authors:  M Oellerich; M Burdelski; H U Lautz; M Schulz; F W Schmidt; H Herrmann
Journal:  Ther Drug Monit       Date:  1990-05       Impact factor: 3.681

2.  Transection of the oesophagus for bleeding oesophageal varices.

Authors:  R N Pugh; I M Murray-Lyon; J L Dawson; M C Pietroni; R Williams
Journal:  Br J Surg       Date:  1973-08       Impact factor: 6.939

3.  The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs and man.

Authors:  J B Keenaghan; R N Boyes
Journal:  J Pharmacol Exp Ther       Date:  1972-02       Impact factor: 4.030

4.  Effect of food on lidocaine kinetics: mechanism of food-related alteration in high intrinsic clearance drug elimination.

Authors:  A T Elvin; A F Cole; J A Pieper; S H Rolbin; D Lalka
Journal:  Clin Pharmacol Ther       Date:  1981-10       Impact factor: 6.875

5.  Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease.

Authors:  J A Forrest; N D Finlayson; K K Adjepon-Yamoah; L F Prescott
Journal:  Br Med J       Date:  1977-05-28

6.  Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4.

Authors:  M J Bargetzi; T Aoyama; F J Gonzalez; U A Meyer
Journal:  Clin Pharmacol Ther       Date:  1989-11       Impact factor: 6.875

7.  Lignocaine metabolite formation as a measure of pre-transplant liver function.

Authors:  M Oellerich; M Burdelski; B Ringe; P Lamesch; G Gubernatis; H Bunzendahl; R Pichlmayr; H Herrmann
Journal:  Lancet       Date:  1989-03-25       Impact factor: 79.321

8.  Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs.

Authors:  T Kronbach; V Fischer; U A Meyer
Journal:  Clin Pharmacol Ther       Date:  1988-06       Impact factor: 6.875

9.  Monoethylglycinexylidide formation kinetics: a novel approach to assessment of liver function.

Authors:  M Oellerich; E Raude; M Burdelski; M Schulz; F W Schmidt; B Ringe; P Lamesch; R Pichlmayr; H Raith; M Scheruhn
Journal:  J Clin Chem Clin Biochem       Date:  1987-12

10.  Extrahepatic production of the lignocaine metabolite monoethylglycinexylidide (MEGX).

Authors:  R W Sallie; J M Tredger; R Williams
Journal:  Biopharm Drug Dispos       Date:  1992-10       Impact factor: 1.627

View more
  1 in total

1.  Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers.

Authors:  Eleonora L Swart; Ben van der Hoven; A B Johan Groeneveld; Daniel J Touw; Meindert Danhof
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.